Fig. 2
From: Effect of menopausal hormone therapy on methylation levels in early and late postmenopausal women
EWAS results for association of methylation levels with time-since-menopause and HT. (A) Manhattan plot shows two CpG sites on chromosomes 12 (cg19552895) and 19 (cg18515510) at which the difference in methylation levels between baseline and 36 months after treatment were significantly associated with time-since-menopause and treatment. Genome-wide methylation was assessed across 748,567 CpG sites and interaction P-values between time-since-menopause and HT for changes in methylation (M-values) from baseline to 36 months post treatment, with adjustment for age, ethnicity, and estimated blood cell fractions, are plotted as a function of genomic location. The solid red and blue lines indicate the significant (p = 6.7 × 10–8) and suggestive (p = 6.7 × 10–6) thresholds for significance, respectively. Regional plots show 400kb intervals on chromosomes 12 and 19 centered on cg19552895 (B) and cg18515510 (C), respectively. Genes located within the 400kb intervals are shown in the bottom panels